Jon J. Vernon - Concepedia

Author

Jon J. Vernon

Also Known As

J J Vernon, J. J. Vernon, J. Vernon, J.J. Vernon, Jane Freeman, Jon J Vernon, Jon J. Vernon, Jon Vernon, Jonathan J. Vernon, Jonathan Vernon

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Leeds Leeds Teaching Hospitals NHS Trust Astellas Pharma (United Kingdom)Leeds General Infirmary Summit (United Kingdom)

About

Jon J. Vernon is an author at University of Leeds specializing in microbiology, medicine, and bacterial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	461
2	Engineering	1	1	18
3	Health Sciences	1	1	28
4	Biomedical Engineering	1	1	14
5	Biomolecular Engineering	1	1	18

Jon J. Vernon

Publications

663

Citations

H-Index

Page 1

	Year	Citations
Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes Jane Freeman, Jon J. Vernon, K. Morris, Clinical Microbiology and Infection Antimicrobial Resistance GeneAntimicrobial SusceptibilityAntibioticsPan-european Longitudinal SurveillanceAntimicrobial Therapy	2014	264
The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011–2014 Jane Freeman, Jon J. Vernon, Sally Pilling, Clinical Microbiology and Infection Antimicrobial SusceptibilityAntibioticsMedicineMicrobiologyInfection Control	2017	134
A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018 Virginie Viprey, Georgina Davis, Anthony Benson, Eurosurveillance	2022	49
<i>In vitro</i> susceptibility of <i>Clostridium difficile</i> to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against <i>C. difficile</i> David F. Corbett, Andrew K. Wise, Stephen Birchall, Journal of Antimicrobial Chemotherapy	2015	40
Dental Mitigation Strategies to Reduce Aerosolization of SARS-CoV-2 Jon J. Vernon, Emma Black, Thomas Dennis, Journal of Dental Research	2021	35
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators Jane Freeman, Jon J. Vernon, Richard Vickers, Antimicrobial Agents and Chemotherapy Clostridium Difficile IsolatesAntimicrobial Resistance PhenotypesAntimicrobial SusceptibilityHealth SciencesAntibiotics	2015	28
Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities Jon J. Vernon, Wilcox Mark H, Jane Freeman Anaerobe Temporal ComparisonAntimicrobial Resistance GeneAntimicrobial SusceptibilityAntibioticsAntimicrobial Therapy	2021	21
Antimicrobial Dye-Conjugated Polyglobalide-Based Organogels Jason V. Rowley, Patrick A. Wall, Huayang Yu, ACS Applied Polymer Materials Straightforward ColorationEngineeringNatural PolymerPolymer ScienceEscherichia Coli	2020	18
Efficacy of vancomycin extended-dosing regimens for treatment of simulated<i>Clostridium difficile</i>infection within an<i>in vitro</i>human gut model G. S. Crowther, C. H. Chilton, Christopher Longshaw, Journal of Antimicrobial Chemotherapy	2016	16
<i>In Vitro</i> Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread Jane Freeman, Sally Pilling, Jon J. Vernon, Antimicrobial Agents and Chemotherapy	2016	16

Page 1